<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Alx Oncology Holdings — News on 6ix</title>
<link>https://6ix.com/company/alx-oncology-holdings</link>
<description>Latest news and press releases for Alx Oncology Holdings on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 17 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/alx-oncology-holdings" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835459178dffbe2df0e29ba.webp</url>
<title>Alx Oncology Holdings</title>
<link>https://6ix.com/company/alx-oncology-holdings</link>
</image>
<item>
<title>ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-reports-inducement-grant-as-permitted-by-the-nasdaq-listing-rules</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-reports-inducement-grant-as-permitted-by-the-nasdaq-listing-rules</guid>
<pubDate>Fri, 17 Apr 2026 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of 800,000 shares of ALX Oncology’s common stock to Jeff Knight, M.P.H., Chief Developmen</description>
</item>
<item>
<title>ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-appoints-jeff-knight-as-chief-development-and-operating-officer</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational</description>
</item>
<item>
<title>ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Fri, 27 Feb 2026 05:00:00 GMT</pubDate>
<description>- Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track</description>
</item>
<item>
<title>ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-to-present-at-upcoming-investor-conferences-in-q1-2026</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-to-present-at-upcoming-investor-conferences-in-q1-2026</guid>
<pubDate>Thu, 19 Feb 2026 13:33:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology”; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in the Wells Fargo Executive Biotech Summit, TD Cowen 46th Annual Health Care Conference, and UBS Biotech Summit. The details of the meetings are as follows: Wells Fargo Executive Biot</description>
</item>
<item>
<title>ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-27-2026</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-27-2026</guid>
<pubDate>Thu, 19 Feb 2026 13:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its fourth quarter and full year 2025 financial results and a business update on Friday, February 27th, 2026 before market open. The company will host a teleconference in conjunction with its financial results pres</description>
</item>
<item>
<title>ALX Oncology Announces Pricing of Underwritten Offering</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-announces-pricing-underwritten-133000287</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-announces-pricing-underwritten-133000287</guid>
<pubDate>Fri, 30 Jan 2026 13:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced the pricing of an underwritten offering of common stock and pre-funded warrants. ALX Oncology is selling 76,979,112 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,574,1</description>
</item>
<item>
<title>New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/data-demonstrate-cd47-expression-level-131500424</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/data-demonstrate-cd47-expression-level-131500424</guid>
<pubDate>Fri, 30 Jan 2026 13:15:00 GMT</pubDate>
<description>- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – - Full data set submitted for presentation at an upcoming scientific conference - SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cance</description>
</item>
<item>
<title>ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-present-44th-annual-160000981</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-present-44th-annual-160000981</guid>
<pubDate>Thu, 08 Jan 2026 16:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer Jason Lettmann and Chief Medical Officer Barbara Klencke will deliver a corporate presentation on Thursday, January 1</description>
</item>
<item>
<title>ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-advances-separate-clinical-133000166</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-advances-separate-clinical-133000166</guid>
<pubDate>Thu, 08 Jan 2026 13:30:00 GMT</pubDate>
<description>- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 – - Third dose cohort initiated in Phase 1 trial of ALX 2004; study remains on track to provide initial safety data in 1H 2026 - SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biot</description>
</item>
<item>
<title>ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-announces-positive-results-130000860</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-announces-positive-results-130000860</guid>
<pubDate>Sun, 07 Dec 2025 13:00:00 GMT</pubDate>
<description>- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92% of patients with untreated indolent non-Hodgkin lymphoma (iNHL) comparing favorably to an approximate 50% historical CR rate for R2 alone - Data indicates combination of evorpacept plus R2 was well-tolerated and provides impressive anti-tumor activity in frontline treatment setting - While longer follow up matures, minimal residual disease (MRD) eradication rate with this novel regimen will</description>
</item>
<item>
<title>ALX Oncology to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-present-upcoming-investor-160000291</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-present-upcoming-investor-160000291</guid>
<pubDate>Tue, 18 Nov 2025 16:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in both the Jefferies Global Healthcare Conference in London and Piper Sandler 37th Annual Global Healthcare Conference in New York. The details of the meetings are</description>
</item>
<item>
<title>ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-reports-third-quarter-131500121</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-reports-third-quarter-131500121</guid>
<pubDate>Fri, 07 Nov 2025 13:15:00 GMT</pubDate>
<description>ASPEN-06 data to be presented at SITC demonstrates that evorpacept drove durable clinical benefit across all efficacy measures in HER2+ gastric cancer patients with high CD47 expression Phase 2 ASPEN-09-Breast Cancer trial remains on track for FPI in Q4 2025 and will evaluate evorpacept efficacy by CD47 expression levels Phase 1 trial for ALX2004, a novel EGFR-targeted ADC, is currently enrolling patients in the second dose cohort and on track to deliver initial safety data in 1H 2026 Cash runwa</description>
</item>
<item>
<title>ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-report-third-quarter-123000758</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-report-third-quarter-123000758</guid>
<pubDate>Thu, 30 Oct 2025 12:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its third quarter 2025 financial results and provide a business update on Friday, November 7th, 2025, before market open. The company will be hosting a teleconference in conjunction with this pre</description>
</item>
<item>
<title>ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-announces-preclinical-data-163000231</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-announces-preclinical-data-163000231</guid>
<pubDate>Thu, 23 Oct 2025 16:30:00 GMT</pubDate>
<description>-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors -Robust body of preclinical data supports ALX2004 differentiation in EGFR-ADC class and continued evaluation in first-in-human trial -Initial safety data from ongoing ALX2004 Phase 1 trial anticipated in the first half of 2026 SOUTH SAN FRANCISCO, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncol</description>
</item>
<item>
<title>ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-present-updated-data-130500728</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-present-updated-data-130500728</guid>
<pubDate>Fri, 03 Oct 2025 13:05:00 GMT</pubDate>
<description>Company will share data demonstrating CD47 overexpression as key predictive biomarker for response with the Company’s lead candidate, evorpacept, in HER2+ gastric cancer SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced updated data from its Phase 2 ASPEN-06 (N</description>
</item>
<item>
<title>ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-appoints-board-member-123000711</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-appoints-board-member-123000711</guid>
<pubDate>Fri, 12 Sep 2025 12:30:00 GMT</pubDate>
<description>Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company’s Board of Directors and will step down from the Board to join ALX as Interim Chief Medical Officer Alan Sandler, M.D. resigns as Chief Medical Officer and will return to his position serving on the Company’s Board of Directors SOUTH SAN FRANCISCO, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Co</description>
</item>
<item>
<title>ALX Oncology to Participate in Upcoming Investor Conferences in September</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-participate-upcoming-investor-160000198</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-participate-upcoming-investor-160000198</guid>
<pubDate>Fri, 29 Aug 2025 16:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Aug. 29, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in both the Cantor Global Healthcare Conference 2025 and H.C. Wainwright 27th Annual Global Investment Conference in New York. The details of the meetings are as fol</description>
</item>
<item>
<title>ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-doses-first-patient-120000977</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-doses-first-patient-120000977</guid>
<pubDate>Tue, 19 Aug 2025 12:00:00 GMT</pubDate>
<description>- A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window -First-in-human trial of ALX2004 builds upon body of positive preclinical data demonstrating dose dependent anti-tumor activity and favorable safety profile -Initial safety data anticipated in first half 2026 SOUTH SAN FRANCISCO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- ALX Oncology</description>
</item>
<item>
<title>ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-reports-second-quarter-200500872</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-reports-second-quarter-200500872</guid>
<pubDate>Tue, 12 Aug 2025 20:05:00 GMT</pubDate>
<description>– Data from ASPEN-06 trial highlights CD47 expression as a key predictive biomarker of greater response to evorpacept in HER2+ Gastric Cancer; updated data to be presented at a medical conference in Q4 2025 – Phase 2 ASPEN-Breast evorpacept trial design updated to enable CD47 and HER2 biomarker-driven strategy in a single-arm study; anticipated interim data readout in Q3 2026 – ALX2004 Phase 1 clinical trial remains on track to enroll first patient in August – Focus on driving ASPEN-Breast and A</description>
</item>
<item>
<title>ALX Oncology to Report Second Quarter 2025 Financial Results on August 12, 2025</title>
<link>https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-report-second-quarter-120000553</link>
<guid isPermaLink="true">https://6ix.com/company/alx-oncology-holdings/news/alx-oncology-report-second-quarter-120000553</guid>
<pubDate>Tue, 05 Aug 2025 12:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced plans to report its second quarter 2025 financial results and a business update on Tuesday, August 12th, 2025, after market close. The company will be hosting a teleconference in conjunction with its financial r</description>
</item>
</channel>
</rss>